Greg Friberg (File photo)
#ESMO20: Amgen team nails down solid early evidence of AMG 510’s potential for NSCLC, unlocking the door to a wave of KRAS programs
The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
